Mankind Pharma Limited has informed the Exchange regarding a press release dated May 21, 2025, titled "Press Release Q4FY25".
MANKIND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Mankind Pharma has submitted a press release to the stock exchange dated May 21, 2025, related to the fourth quarter of FY25 (Q4FY25). The filing itself is a routine intimation informing the exchange about the press release, which typically accompanies the company's quarterly earnings announcement. The actual financial numbers, segment performance, and management commentary would be detailed within the press release document, which is not included in this brief filing text. Investors should refer to the full press release and the Q4FY25 results for revenue, profit, and growth metrics.
This is a standard regulatory disclosure signalling that Q4FY25 earnings are being shared with the public; the actual stock reaction will depend on the financial numbers contained in the full press release rather than this intimation.